C. Quon

发表

Pharmacology and Pharmacokinetics of Esmolol

R. Reynolds, R. Gorczynski, C. Quon, 1986, Journal of clinical pharmacology.

Clinical pharmacokinetics and pharmacodynamics of colloidal plasma volume expanders

C. Quon, 1988 .

The pharmacokinetics and pharmacodynamics of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) in the dog.

Y. Wong, D. Christ, P. Wong, 1994, The Journal of pharmacology and experimental therapeutics.

Pharmacokinetics of the inodilator XB513 in mice, rats, guinea pigs, rabbits, dogs, and monkeys.

H. Stampfli, C. Quon, S. -. Huang, 1994, Biopharmaceutics & drug disposition.

Separation of R(+)-and S(-)-benzyl-3-tetrahydrofuroates using two different chiral columns

H. Stampfli, C. Quon, R. Sato, 1990 .

Binding of fosphenytoin, phosphate ester pro drug of phenytoin, to human serum proteins and competitive binding with carbamazepine, diazepam, phenobarbital, phenylbutazone, phenytoin, valproic acid or warfarin.

C. Lai, P. Moore, C. Quon, 1995, Research communications in molecular pathology and pharmacology.

Phase I Trial of 2-Methoxyestradiol NanoCrystal Dispersion in Advanced Solid Malignancies

G. Wilding, A. Tevaarwerk, Amye J. Tevaarwerk, 2009, Clinical Cancer Research.

PT‐141: A Melanocortin Agonist for the Treatment of Sexual Dysfunction

P. Molinoff, L. Diamond, C. Quon, 2003, Annals of the New York Academy of Sciences.

Mono- and bis(aminomethyl)phenylacetic acid esters as short-acting antiarrhythmic agents. 2.

V V Ranade, V. Ranade, D. Stout, 1993, Journal of medicinal chemistry.

Ester derivatives of 2,6-bis(1-pyrrolidinylmethyl)-4-benzamidophenol as short-acting antiarrhythmic agents. 1.

D. Stout, D M Stout, L A Black, 1989, Journal of medicinal chemistry.

Species differences in the stereoselective hydrolysis of esmolol by blood esterases.

C Y Quon, H F Stampfli, K Mai, 1988, Drug metabolism and disposition: the biological fate of chemicals.

Biochemical properties of blood esmolol esterase.

C Y Quon, H F Stampfli, H. Stampfli, 1985, Drug metabolism and disposition: the biological fate of chemicals.

Pharmacokinetics, pharmacodynamics, and minimum effective clinical dose of intravenous nicardipine

S. Grandy, G. McMahon, R. Vargas, 1990, Clinical pharmacology and therapeutics.

Bioavailability Studies of Drugs with Nonlinear Pharmacokinetics: II. Absolute Bioavailability of Intravenous Phenytoin Prodrug at Therapeutic Phenytoin Serum Concentrations Determined by Double‐Stable Isotope Technique

T. Browne, G. Szabo, J. Evans, 1993, Journal of clinical pharmacology.

Safety, Tolerance and Pharmacokinetics of Intravenous Doses of the Phosphate Ester of 3‐Hydroxymethyl‐5,5‐Diphenylhydantoin: A New Prodrug of Phenytoin

R. Guthrie, D. Mays, N. Gerber, 1988, Journal of clinical pharmacology.

Bioavailability of ACC‐9653 (Phenytoin Prodrug)

J. E. Evans, B. Jamerson, J. Powell, 1989, Epilepsia.

The Effect of Absorption Enhancers on the Oral Absorption of the GP IIB/IIIA Receptor Antagonist, DMP 728, in Rats and Dogs

Shiew-Mei Huang, M. Hussain, Shiew-Mei Huang, 1995, Pharmaceutical Research.

A pharmacokinetic evaluation of HIV protease inhibitors, cyclic ureas, in rats and dogs

Y. Wong, Shiew-Mei Huang, D. L. Burcham, 1994, Biopharmaceutics & drug disposition.

Beta-adrenoreceptor antagonist potency and pharmacodynamics of ASL-8123, the primary acid metabolite of esmolol.

R. Gorczynski, J. Shaffer, C. Quon, 1988, Journal of cardiovascular pharmacology.

Pharmacodynamics and onset of action of esmolol in anesthetized dogs.

R. Gorczynski, C. Quon, 1986, The Journal of pharmacology and experimental therapeutics.

Protein binding of brequinar in the plasma of healthy donors and cancer patients and analysis of the relationship between protein binding and pharmacokinetics in cancer patients

J. Bertino, H. Pieniaszek, Cecilia L Chi, 2004, Cancer Chemotherapy and Pharmacology.

Activity of 2 methoxyestradiol (Panzem NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial.

D. Matei, S. Perkins, J. Schilder, 2009, Gynecologic oncology.

Influence of temperature on in vitro metabolism of esmolol.

J. Melendez, E. Delphin, J. Stone, 1990, Journal of cardiothoracic anesthesia.

Pharmacokinetics of HIV protease inhibitor DMP 323 in rats and dogs.

Y. Wong, D. L. Burcham, M. Grubb, 1994, Drug metabolism and disposition: the biological fate of chemicals.

HPLC-EC Assay for the Inodilator EXP513 and Its Application in a Dog Pharmacokinetic Study

H. Stampfli, C. Quon, C. Person, 1992 .

Integrated Pharmacokinetic/Pharmacodynamic Model of XV459, a Potent and Specific GPIIb/IIIa Inhibitor, in Healthy Male Volunteers

W. Ebling, J. Barrett, H. Pieniaszek, 2002, Journal of clinical pharmacology.

Synthesis, corticotropin-releasing factor receptor binding affinity, and pharmacokinetic properties of triazolo-, imidazo-, and pyrrolopyrimidines and -pyridines.

C. Hodge, Y. Wong, F. Hobbs, 1999, Journal of medicinal chemistry.

Determination of DuP 128, an ACAT inhibitor and its sulphoxide and sulphone metabolites in human plasma by liquid chromatography.

H. Pieniaszek, B. Brogdon, C. Lai, 1994, Journal of pharmaceutical and biomedical analysis.

Polymorphic metabolism of flestolol and other ester containing compounds by a carboxylesterase in New Zealand white rabbit blood and cornea.

H. Stampfli, C. Quon, 1995, Research communications in molecular pathology and pharmacology.